A prospective phase II clinical trial to determine the efficacy of palbociclib in AM tumors that have CDK4 and/or CCND1 amplification and/or CDKN2A loss is currently underway (Clinical Trials ID: NCT03454919). This evidence concerns the gene CDKN2A and acute myeloblastic leukemia with maturation.